Mave Health, a healthtech startup founded in 2023, has successfully raised $2.1 million in a seed funding round led by Blume Ventures. This funding will support the launch of its transcranial direct current stimulation (tDCS) wearable headset in the United States and India, along with expanding its manufacturing capabilities.
The headset is designed to enhance focus, mood, and stress regulation by delivering low-intensity electrical signals to the brain. Currently available for pre-order, the device is expected to start shipping in April 2026.
Key Features of the Wearable Headset
- Non-invasive Technology: The headset uses non-invasive brain stimulation to regulate neural activity.
- Daily Use: Designed for a 20-minute daily wear, it can last up to a month on a single charge.
- Targeted Stimulation: It focuses on the prefrontal cortex, which is crucial for attention and emotional regulation.
User Impact
Mave Health reports that 80% of users experience over a 60% increase in productivity and 75% see reduced stress levels within four weeks of using the headset. Additionally, users have noted an average mood improvement of 77%.
Market Context
The funding comes at a time when India's healthtech wearables market is evolving from basic fitness tracking to advanced health monitoring solutions. This shift is expected to play a significant role in the broader healthtech landscape.
With this latest funding, Mave Health's total funding has reached nearly $3 million, including a previous $750,000 pre-seed round in 2023. The company aims to position itself as a leader in the mental health wearable market, alongside other emerging startups.
